Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus
Diabetes & Metabolism Journal
; : 711-717, 2019.
Artículo
en Inglés
| WPRIM (Pacífico Occidental)
| ID: wpr-763676
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND:
The study aimed to evaluate the effects of dapagliflozin and metformin on vascular endothelial function and renal injury markers.METHODS:
This prospective, randomized, open-label, crossover study included drug-naïve patients with type 2 diabetes mellitus, who were randomized to receive 8 weeks of initial treatment using metformin or dapagliflozin and crossed over for another 8 weeks of treatment after a 1-week washout period. Systemic endothelial function was evaluated via the reactive hyperemic index (RHI).RESULTS:
The 22 participants included 10 males (45.5%) and had a median age of 58 years. The RHI values were not significantly changed during both 8-week treatment periods and there was no significant difference between the treatments. Relative to the metformin group, 8 weeks of dapagliflozin treatment produced significantly higher median N-acetyl-beta-D-glucosaminidase levels (10.0 ng/mL [interquartile range (IQR), 6.8 to 12.1 ng/mL] vs. 5.6 ng/mL [IQR, 3.8 to 8.0 ng/mL], P=0.013). Only the dapagliflozin group exhibited improved homeostatic model assessment of insulin resistance and body weight, while serum ketone and β-hydroxybutyrate levels increased.CONCLUSION:
Dapagliflozin treatment did not affect systemic endothelial function or renal injury markers except N-acetyl-beta-D-glucosaminidase.
Texto completo:
Disponible
Contexto en salud:
Agenda de Salud Sostenible para las Américas
/
ODS3 - Salud y Bienestar
Problema de salud:
Objetivo 9: Enfermedades no transmisibles y salud mental
/
Meta 3.4: Reducir las muertes prematuras por enfermedades no transmisibles
Base de datos:
WPRIM (Pacífico Occidental)
Asunto principal:
Acetilglucosaminidasa
/
Peso Corporal
/
Resistencia a la Insulina
/
Estudios Prospectivos
/
Estudios Cruzados
/
Manejo de la Enfermedad
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Metformina
Tipo de estudio:
Ensayo clínico controlado
/
Estudio observacional
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Diabetes & Metabolism Journal
Año:
2019
Tipo del documento:
Artículo